Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abatacept - Bristol-Myers Squibb

Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: Abata - Bristol-Myers Squibb; BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 23 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Cambridge University Hospitals; Columbia University; National Institute for Health Research; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Hospital, Brest; University Medical Center Freiburg; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoglobulin fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Skin disorder therapies; Urologics
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Giant cell arteritis; Myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Registered Graft-versus-host disease
  • Phase III COVID 2019 infections; Dermatomyositis; Lupus nephritis; Myositis; Polymyalgia rheumatica; Polymyositis
  • Phase II Alopecia areata; Common variable immunodeficiency; Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome; Pulmonary sarcoidosis
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Inflammation; Multiple sclerosis; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 12 Jun 2024 Adverse events and efficacy data from a phase III trial in Myositis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 12 Jun 2024 Efficacy and adverse event data from a phase III trial in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 10 Nov 2023 Pharmacodynamics data from a phase III AVERT-2 trial in Rheumatoid arthritis presented at the American College of Rheumatology Convergence 2023 (ACR-ARP-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top